Shenzhen Hlongmed Biotech Co.,Ltd. – Trademark Portfolio

Entity Type: 99

Shenzhen Hlongmed Biotech Co.,Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include AMEDPRIME. The owner is based in Shenzhen City ,Guangdong Province.

Room 1609,Tianming Technology Building, No.8 Wushitou Road, Songpingshan Community, Xili Sub-district, Nanshan District

Shenzhen City ,Guangdong Province 518055 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

AMEDPRIME
AMEDPRIME
Registered 2025

Trademark Classifications

Shenzhen Hlongmed Biotech Co.,Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Shenzhen Hlongmed Biotech Co.,Ltd. have?

Shenzhen Hlongmed Biotech Co.,Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Shenzhen Hlongmed Biotech Co.,Ltd. file in?

Shenzhen Hlongmed Biotech Co.,Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Shenzhen Hlongmed Biotech Co.,Ltd.'s most well-known trademarks?

Shenzhen Hlongmed Biotech Co.,Ltd.'s registered trademark portfolio includes well-known marks such as AMEDPRIME. These are among 1 currently registered trademark in the portfolio.

What is Shenzhen Hlongmed Biotech Co.,Ltd.'s trademark registration success rate?

Shenzhen Hlongmed Biotech Co.,Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.